RecruitingNCT06521047
A Multicentre Observational Study to Assess Long-term Outcome of Participants in the EXCELLENT Clinical Trial
Sponsor
CellProthera
Enrollment
48 participants
Start Date
Jul 20, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The PERFECT study is an observational study designed to follow patients randomised in the EXCELLENT study (NCT02669810) for 10 years. The aim is to assess the long-term clinical outcomes for patients randomised to the Standard of Care arm or the ProtheraCytes arm.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Completion of the last visit in the EXCELLENT interventional clinical trial.
- Participation must be within 10 years after the randomization in the EXCELLENT trial
Exclusion Criteria2
- Patients randomized to the ProtheraCytes® group who did not receive the product of the EXCELLENT Trial are excluded.
- Any other coexisting conditions that will preclude participation in the study or compromise ability to give informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERNA - Observational study
Observational study, data collection only.
Locations(10)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06521047
Related Trials
Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention
NCT075368022 locations
Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.
NCT047432451 location
Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE
NCT063363173 locations
SUBDIMA: Subclinical Depression in Acute Myocardial Infarction (SUBDIMA25)
NCT074925371 location
Multi-center Collaborative to Enhance Quality and Outcomes in the Management of Cardiogenic Shock
NCT051854923 locations